Showing 9,021 - 9,040 results of 32,444 for search '(( a step decrease ) OR ( 50 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.06s Refine Results
  1. 9021

    Reducing inherent biases introduced during DNA viral metagenome analyses of municipal wastewater by Nichole E. Brinkman (5052314)

    Published 2018
    “…<div><p>Metagenomics is a powerful tool for characterizing viral composition within environmental samples, but sample and molecular processing steps can bias the estimation of viral community structure. …”
  2. 9022
  3. 9023
  4. 9024

    Enantiomeric Deoxycholic Acid:  Total Synthesis, Characterization, and Preliminary Toxicity toward Colon Cancer Cell Lines by Bryson W. Katona (2465581)

    Published 2007
    “…Using a modified method of the synthesis of <i>ent</i>-testosterone that proceeds through the (<i>R</i>)-(−)-Hajos−Parrish ketone, we have completed the successful synthesis of <i>ent</i>-DCA in 25 steps with a yield of 0.3% with all stereochemical assignments of the product confirmed by X-ray crystallography. …”
  5. 9025

    Enantiomeric Deoxycholic Acid:  Total Synthesis, Characterization, and Preliminary Toxicity toward Colon Cancer Cell Lines by Bryson W. Katona (2465581)

    Published 2007
    “…Using a modified method of the synthesis of <i>ent</i>-testosterone that proceeds through the (<i>R</i>)-(−)-Hajos−Parrish ketone, we have completed the successful synthesis of <i>ent</i>-DCA in 25 steps with a yield of 0.3% with all stereochemical assignments of the product confirmed by X-ray crystallography. …”
  6. 9026

    Enantiomeric Deoxycholic Acid:  Total Synthesis, Characterization, and Preliminary Toxicity toward Colon Cancer Cell Lines by Bryson W. Katona (2465581)

    Published 2007
    “…Using a modified method of the synthesis of <i>ent</i>-testosterone that proceeds through the (<i>R</i>)-(−)-Hajos−Parrish ketone, we have completed the successful synthesis of <i>ent</i>-DCA in 25 steps with a yield of 0.3% with all stereochemical assignments of the product confirmed by X-ray crystallography. …”
  7. 9027

    Enantiomeric Deoxycholic Acid:  Total Synthesis, Characterization, and Preliminary Toxicity toward Colon Cancer Cell Lines by Bryson W. Katona (2465581)

    Published 2007
    “…Using a modified method of the synthesis of <i>ent</i>-testosterone that proceeds through the (<i>R</i>)-(−)-Hajos−Parrish ketone, we have completed the successful synthesis of <i>ent</i>-DCA in 25 steps with a yield of 0.3% with all stereochemical assignments of the product confirmed by X-ray crystallography. …”
  8. 9028

    Lists of predicted adverse events. by Soohyun Wi (18536612)

    Published 2024
    “…The early rehabilitation of critically ill patients can reduce the ICU-AW. We designed a protocol to investigate the feasibility and safety of conventional rehabilitation with additional in-bed cycling/stepping in critically ill patients.…”
  9. 9029

    Clinical examination items. by Soohyun Wi (18536612)

    Published 2024
    “…The early rehabilitation of critically ill patients can reduce the ICU-AW. We designed a protocol to investigate the feasibility and safety of conventional rehabilitation with additional in-bed cycling/stepping in critically ill patients.…”
  10. 9030

    Inclusion and exclusion criteria. by Soohyun Wi (18536612)

    Published 2024
    “…The early rehabilitation of critically ill patients can reduce the ICU-AW. We designed a protocol to investigate the feasibility and safety of conventional rehabilitation with additional in-bed cycling/stepping in critically ill patients.…”
  11. 9031

    Effect of Cytosolic pH on Inward Currents Reveals Structural Characteristics of the Proton Transport Cycle in the Influenza A Protein M2 in Cell-Free Membrane Patches of <i>Xenopus... by Mattia L. DiFrancesco (364045)

    Published 2014
    “…Assuming an additional transport step as e.g. caused by a constriction zone at Val27 resulted in a negligible improvement. …”
  12. 9032
  13. 9033

    Activity of miR-124 and miR-23a in NSC-derived neurons and astrocytes. by Annalisa Lattanzi (427545)

    Published 2013
    “…(B–E) A significant decrease of GFP expression is observed in bdLV.miRT124-transduced neurons (βtubIII, MAP2) (<b>B, C</b>) and in bdLV.miRT23a-transduced astrocytes (GFAP) and immature glial cells (nestin) (<b>D, E</b>). …”
  14. 9034
  15. 9035
  16. 9036

    The effect of glibenclamide on channel activity at +20, 0 and -20 mV. by Sajjad Salari (736104)

    Published 2015
    “…Histogram bars show current amplitudes and P<sub>o</sub> of reconstituted channels in absence or presence of glibenclamide. The addition of 50 μM glibenclamide resulted in a decreased current jump amplitude and a reduction in P<sub>o</sub>. 100 μM glibenclamide caused a total channel inhibition at +20 and 0 mV (n = 5), but was ineffective at -20 mV. …”
  17. 9037
  18. 9038

    Crystal Structure of YbCu<sub>6</sub>In<sub>6</sub> and Mixed Valence Behavior of Yb in YbCu<sub>6–<i>x</i></sub>In<sub>6+<i>x</i></sub> (<i>x</i> = 0, 1, and 2) Solid Solution by Udumula Subbarao (1431364)

    Published 2016
    “…A deviation in inverse susceptibility data at 200 K suggests a valence transition from Yb<sup>2+</sup> to Yb<sup>3+</sup> as the temperature decreases. …”
  19. 9039

    Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

    Published 2022
    “…Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …”
  20. 9040

    Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

    Published 2022
    “…Toward validating this receptor as a target in SCI, we have developed a new series of LPA<sub>2</sub> antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA<sub>2</sub> receptor antagonist (<i>E</i><sub>max</sub> = 90%, IC<sub>50</sub> = 1.9 μM, <i>K</i><sub>D</sub> = 1.3 nM; inactive at LPA<sub>1,3–6</sub> receptors). …”